Analysis Tools
immune system
|
• mice treated with 1% dextran sodium sulfate (DSS) for 10 days show only a slight loss of body weight, mild diarrhea, and marginal changes in the bloody stool score relative to DSS-treated wild-type controls
• DSS-treated mice show longer colon length, less edema and inflammation in the distal colon, and absence of infiltrating immune cells in the lamina propria relative to DSS-treated wild-type controls
|
|
• following i.p. injection of tri-DAP (an NOD1 ligand), no increase in monocyte chemoattractant protein-1 (MCP-1) is detectable in serum, unlike in wild-type controls
|
|
• following i.p. injection of tri-DAP, no increase in interleukin-1 beta is detectable in serum, unlike in wild-type controls
|
|
• following i.p. injection of tri-DAP, no increase in interleukin-6 is detectable in serum, unlike in wild-type controls
|
|
• mice exhibit impaired TLR9-and NOD1-mediated cytokine production
• adding exogenous histidine has only a small inhibitory effect on TLR9-mediated cytokine production by DCs
• following i.p. injection of tri-DAP (an NOD1 ligand), no secretion of monocyte chemoattractant protein-1 (MCP-1) is detectable in peritoneal lavages, unlike in wild-type controls
• however, muramyl dipeptide (MDP)-dependent cytokine production is unaffected
|
|
• following stimulation with CpG oligodeoxynucleotide (CpG-ODN, a ligand for Toll-like receptor 9), mRNA levels of interferon-beta in DCs are significantly lower than those in wild-type DCs
|
|
• following stimulation with CpG-ODN, mRNA levels of interleukin-1 beta in DCs are significantly lower than those in wild-type DCs
• following i.p. injection of tri-DAP, secretion of interleukin-1 beta in peritoneal lavages and culture supernatants of peritoneal exudate cells is significantly lower than that in wild-type controls
|
|
• following stimulation with CpG-ODN, secretion of interleukin-12 p70 by DCs is significantly lower than that of wild-type DCs
|
|
• following stimulation with CpG-ODN, mRNA levels of interleukin-12 p40 in DCs are significantly lower than those in wild-type DCs
|
|
• following stimulation with CpG-ODN, mRNA levels of interleukin-15 in DCs are significantly lower than those in wild-type DCs
|
|
• following stimulation with CpG-ODN, mRNA levels of interleukin-18 in DCs are significantly lower than those in wild-type DCs
|
|
• following i.p. injection of tri-DAP, no secretion interleukin-6 is detectable in peritoneal lavages, unlike in wild-type controls
|
|
• following stimulation with CpG-ODN, mRNA levels and secretion of tumor necrosis factor-alpha by DCs are significantly lower than those in wild-type DCs
|
homeostasis/metabolism
|
• following i.p. injection of tri-DAP (an NOD1 ligand), no increase in monocyte chemoattractant protein-1 (MCP-1) is detectable in serum, unlike in wild-type controls
|
|
• following i.p. injection of tri-DAP, no increase in interleukin-1 beta is detectable in serum, unlike in wild-type controls
|
|
• following i.p. injection of tri-DAP, no increase in interleukin-6 is detectable in serum, unlike in wild-type controls
|
digestive/alimentary system
|
• mice treated with 1% dextran sodium sulfate (DSS) for 10 days show only a slight loss of body weight, mild diarrhea, and marginal changes in the bloody stool score relative to DSS-treated wild-type controls
• DSS-treated mice show longer colon length, less edema and inflammation in the distal colon, and absence of infiltrating immune cells in the lamina propria relative to DSS-treated wild-type controls
|
